| Literature DB >> 34876901 |
Yonghoon Lee1, Michael P Guertin1, Spencer Summers2, Sheila A Conway3, Mothasem Al Maaieh4, Raphael Yechieli5, Jonathan Trent5, Andrew E Rosenberg6, Juan Pretell-Mazzini7.
Abstract
BACKGROUND: Myxofibrosarcoma (MFS) is notorious for its infiltrative growth pattern, making wide excisions difficult to achieve. Our objective was to assess the impact of surgical margins and other factors that affected rates of local recurrence (LR), distant metastasis (DM), and overall survival (OS) of individuals undergoing resection for MFS.Entities:
Year: 2021 PMID: 34876901 PMCID: PMC8645367 DOI: 10.1155/2021/1844816
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Figure 1(a) Ax-T2-MR demonstrating tumor with infiltrating margins in subcutaneous fat. (b) Tumor in subcutis with infiltrative tentacles (arrows). (c) Tumor with malignant spindle cells infiltrating fat, present at the ink surface. (d) Negative margin with tumor confined by pseudocapsule (arrow).
Demographics and tumor descriptions for each patient.
| Patient ID | Gender | Race | Age | Location, left/right | Location, upper/lower | Tumor depth | Tumor character | Tumor grade | Tumor stage | Total follow-up time (years) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | W | 57 | Left | Lower | SQ | Inf | 3/3 | Stage IIIA | 2.32 |
| 2 | M | W | 74 | Right | Lower | IM | WC | 3/3 | Stage II | 5.73 |
| 3 | M | W | 66 | Left | Lower | SQ | Inf | 3/3 | Stage IIIB | 3.38 |
| 4 | M | H | 77 | Right | Upper | IM | WC | 3/3 | Stage IIIA | 5.82 |
| 5 | M | W | 56 | Left | Lower | SQ | WC | 3/3 | Stage IIIB | 5.56 |
| 6 | F | W | 64 | Left | Lower | SQ | WC | 3/3 | Stage IIIB | 2.47 |
| 7 | F | W | 67 | Right | Lower | IM | WC | 3/3 | Stage IIIA | 4.08 |
| 8 | M | AA | 46 | Left | Lower | IM | WC | 3/3 | Stage II | 2.78 |
| 9 | F | W | 82 | Left | Upper | IM | Inf | 2/3 | Stage IIIB | 5.12 |
| 10† | M | W | 90 | Left | Lower | SQ | WC | 3/3 | Stage IV | 2.51 |
| 11 | F | AA | 65 | Right | Lower | SQ | WC | 3/3 | Stage IIIB | 1.3 |
| 12 | M | W | 54 | Right | Lower | SQ | Inf | 3/3 | Stage IIIB | 2.34 |
| 13 | F | As | 54 | Left | Lower | SQ | WC | 3/3 | Stage II | 6.25 |
| 14 | M | W | 66 | Left | Lower | SQ | Inf | 3/3 | Stage IIIB | 1.85 |
| 15 | F | W | 83 | Left | Lower | IM | WC | 3/3 | Stage IIIB | 6.63 |
| 16 | M | AA | 62 | Right | Upper | IM | WC | 2/3 | Stage II | 3.38 |
| 17 | F | W | 53 | Left | Lower | IM | WC | 2/3 | Stage IIIB | 3.75 |
| 18 | M | W | 59 | Left | Lower | IM | Inf | 3/3 | Stage II | 6.35 |
| 19 | F | W | 88 | Left | Lower | IM | WC | 2/3 | Stage IIIB | 3.82 |
| 20 | M | W | 47 | Left | Lower | SQ | Inf | 3/3 | Stage IIIA | 5.79 |
| 21 | M | W | 47 | Left | Lower | SQ | Inf | 3/3 | Stage II | 5.84 |
| 22 | M | AA | 67 | Left | Lower | IM | WC | 3/3 | Stage IIIB | 5.5 |
| 23 | M | W | 78 | Right | Lower | IM | Inf | 3/3 | Stage IIIB | 0.36 |
| 24 | F | W | 85 | Left | Lower | IM | Inf | 3/3 | Stage II | 3.02 |
| 25 | F | W | 64 | Left | Lower | IM | WC | 3/3 | Stage II | 2.91 |
| 26 | F | W | 67 | Right | Lower | IM | WC | 3/3 | Stage II | 3.66 |
| 27 | M | AA | 46 | Left | Lower | IM | WC | 3/3 | Stage II | 2.78 |
| 28 | M | W | 55 | Right | Upper | SQ | WC | 3/3 | Stage II | 2.42 |
| 29 | M | W | 63 | Right | Lower | SQ | Inf | 2/3 | Stage IIIB | 2.12 |
Note. M = male; F = female; W = white; AA = African American; H = Hispanic; As = Asian; SQ = subcutaneous; IM = intramuscular; Inf = infiltrative; WC = well-circumscribed; = one additional resection; † = three additional resections.
Relationship between oncological outcomes and 2-year local recurrence-free rates.
| Oncological outcomes | 2-year LR over total | 2-year LRFR (%) | HR | 95% CI |
| |
|---|---|---|---|---|---|---|
| Tumor type | Myxofibrosarcoma | 7/33 | 79 | |||
| Gender | Male | 4/17 | 76 | 2.33 | 0.24–22.44 | 0.46 |
| Female | 1/12 | 92 | ||||
|
| ||||||
| Age | ≤60 years old | 1/11 | 91 | 0.50 | 0.05–4.80 | 0.55 |
| >60 years old | 4/18 | 78 | ||||
|
| ||||||
| Tumor size | ≤10 cm | 7/20 | 65 | N/A | 44–86% | 0.02 |
| >10 cm | 0/13 | 100 | ||||
|
| ||||||
| Margin size | Negative ≤0.1 cm | 3/8 | 63 | 7.97 | 0.83–76.79 | 0.07 |
| Negative >0.1 cm | 1/18 | 94 | ||||
|
| ||||||
| Surgical margins | Positive | 3/7 | 57 | — | — | — |
| Close margins | 3/8 | 63 | 0.95 | 0.19–4.73 | 0.95 | |
| Negative >0.1 cm | 1/18 | 94 | 0.11 | 0.01–1.07 | 0.06 | |
|
| ||||||
| Grouped surgical margins | Positive or close | 6/13 | 54 | 11.74 | 1.41–97.74 | 0.02 |
| Negative >0.1 cm | 1/20 | 95 | ||||
|
| ||||||
| Tumor depth | Subcutaneous | 5/17 | 71 | 2.56 | 0.50–13.21 | 0.26 |
| Intramuscular | 2/16 | 88 | ||||
|
| ||||||
| Tumor character | Well-circumscribed | 2/18 | 89 | 0.30 | 0.06–1.54 | 0.15 |
| Infiltrative | 5/15 | 67 | ||||
|
| ||||||
| Re-resection intraoperatively† | Re-resection done | 2/4 | 50 | N/A | 1–99% | 0.19 |
| Re-resection not done | 0/3 | 0 | ||||
|
| ||||||
| Re-resection postoperativelyˆ | Re-resection done | 0/4 | 100 | N/A | 100% | 0.07 |
| Re-resection not done | 2/3 | 67% | ||||
|
| ||||||
| Adjuvant therapy | Chemotherapy and radiotherapy | 0/17 | 100% | N/A | 100% | 0.001 |
| Chemotherapy alone | 3/4 | 25% | ||||
| Radiotherapy alone | 2/8 | 75% | ||||
| No treatment | 2/4 | 50% | ||||
Note. LRFR = 2-year local recurrence-free rate; LR = local recurrence; HR = hazard ratio; CI = confidence interval. Close margins = negative margins ≤0.1 cm; the Kaplan–Meier log-ranked test was used to assess statistical significance; †re-resections were done intraoperatively due to positive intraoperative pathology report; ˆre-resections were done postopearatively due to positive final pathology report.
Figure 2Figure showing the 2-year local recurrence-free rate comparing patients with negative margins >0.1 cm and patients with either negative margins <0.1 cm or positive margins.
Figure 32-year local recurrence rates (LRRs) compared between (1) all patients, (2) a second recurrence in patients who had a LR, (3) patients with a re-resection after positive final pathology reports, and (4) patients without a re-resection after positive final pathology reports.
Relationship between oncological outcomes and 2-year metastatic-free rates.
| Oncological Outcome | 2-year MR over total | 2-year MFR | HR | 95% CI |
| |
|---|---|---|---|---|---|---|
| Gender | Male | 1/17 | 94% | 9.2 | 1.07–79.16 | 0.043 |
| Female | 5/12 | 58% | ||||
Note. MR = metastatic rate; MFR = metastatic-free rate; HR = hazard ratio; CI = confidence interval.
Relationship between oncological outcomes and 2-year overall survival rates.
| Oncological outcome | Kaplan–Meier log-rank test | Cox regression | |||||
|---|---|---|---|---|---|---|---|
| 2-year SR over total | 2-year OSR (%) |
| HR | 95% CI |
| ||
| Recurrence | Yes | 3/6 | 50 | 0.02 | 6.36 | 1.06–38.21 | 0.043 |
| No | 2/23 | 91 | |||||
Note. SR = survival rate; OSR = overall survival rate; HR = hazard ratio; CI = confidence interval.